| Title |
Optimal management of digital ulcers in systemic sclerosis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, June 2015
|
| DOI | 10.2147/tcrm.s82561 |
| Pubmed ID | |
| Authors |
Shawn Abraham, Virginia Steen |
| Abstract |
Raynaud's phenomenon and digital ulcerations are two common clinical features seen in patients with systemic sclerosis. They are painful and lead to significant morbidity and altered hand function within this patient population. While currently there are no US Food and Drug Administration (FDA)-approved medications for the treatment of digital ulcerations in the United States, clinical trials have supported the use of pharmacologic and nonpharmacologic modalities in facilitating healing of existing digital ulcers and preventing formation of new ulcers. This article reviews the published data on these therapeutic options. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 20% |
| Mexico | 1 | 10% |
| United Kingdom | 1 | 10% |
| Unknown | 6 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 60% |
| Practitioners (doctors, other healthcare professionals) | 4 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 2% |
| Unknown | 59 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 17% |
| Student > Postgraduate | 9 | 15% |
| Other | 8 | 13% |
| Student > Ph. D. Student | 5 | 8% |
| Student > Bachelor | 4 | 7% |
| Other | 10 | 17% |
| Unknown | 14 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 47% |
| Nursing and Health Professions | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Business, Management and Accounting | 1 | 2% |
| Other | 5 | 8% |
| Unknown | 17 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2022.
All research outputs
#2,871,238
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#133
of 1,308 outputs
Outputs of similar age
#35,819
of 281,752 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 43 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.